Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

Almario (Once daily) OBSproton pump inhibitors (PPI)controlCOVID-19 prophylaxis (excluding children)serious
14855/36583 safety concern
  • statistically significant 1.2-fold increase in new illness compatible with Covid-19 but with a low degree of certainty due to high risk of bias
In another regression analysis among the overall cohort that included duration of antisecretory use, regarding PPI exposure: no current PPI use—reference; up to once-daily PPI for ⩽ 6 months—aOR 3.25 (95% CI, 2.81–3.77); up to once-daily PPI use for > 6 months—aOR 1.44 (95% CI, 1.22–1.70).
Almario (Twice daily) OBSproton pump inhibitors (PPI)controlCOVID-19 prophylaxis (excluding children)serious
1692/36583 safety concern
  • statistically significant 2.7-fold increase in new illness compatible with Covid-19 but with a low degree of certainty due to high risk of bias
Ullah (COVID-19 Onset) OBSproton pump inhibitors (PPI)controlCOVID-19 prophylaxis (excluding children)NA
4533/9678 safety concern
  • statistically significant 53 % increase in conversion to SARS-CoV- 2–positive status via NP swab
Lee (COVID-19 onset) OBSproton pump inhibitors (PPI)controlCOVID-19 prophylaxis (excluding children)critical
13873/13873 inconclusive
  • inconclusive 10 % decrease in symptomatic Covid-19 (PE) but with a very low degree of certainty due to critical risk of bias
Blanc OBSproton pump inhibitors (PPI)controlCOVID-19 prophylaxis (excluding children)NA
89/90 suggested
  • suggested 56 % decrease in conversion to SARS-CoV- 2–positive status via NP swab
McKeigue (REACT-SCOT)
  EUPAS35558		 OBSproton pump inhibitors (PPI)controlCOVID-19 prophylaxis (excluding children)NA
4272/36948 safety concern
  • statistically significant 44 % increase in death or transfer to ICU

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons